Before nonanimal toxicity tests may be officially accepted by regulatory agencies, it is generally agreed that the validity of the new methods must be demonstrated in an independent, scientifically sound validation program. Validation has been defined as the demonstration of the reliability and relevance of a test method for a particular purpose. This paper provides a brief review of the development of the theoretical aspects of the validation process and updates current thinking about objectively testing the performance of an alternative method in a validation study. Validation of alternative methods for eye irritation testing is a specific example illustrating important concepts. Although discussion focuses on the validation of alternative methods intended to replace current in vivo toxicity tests, the procedures can be used to assess the performance of alternative methods intended for other uses.
Introduction
The use of animals for routine toxicity testing is now questioned by a growing segment of society. The expression of this concern is seen with particular darity in the 6th Amendment to the European Union Cosmetics Directive (1). This directive contains a provision that it will become illegal to market cosmetic products in European Union countries if they contain ingredients or mixtures of ingredients that have been tested in animals (to meet the purposes of the directive) unless there are no valid alternatives to replace the animal tests. New test procedures are now being developed to meet ethical concerns and to provide improved toxicologic information. It is critically important to determine whether such alternative methods are valid for use in the safety assessment process.
If alternative methods are to be successfully incorporated into the safety assessment process, it will be necessary to demonstrate that the new procedures can provide at least an equivalent level of protection to that obtained with current methods (1). Additionally, if deadlines imposed by legislation such as the 6th Amendment to the European Union Cosmetics Directive are to be met, it is important that the validation process be conducted in a manner that efficiently and definitively characterizes the performance of the alternative methods.
Important concepts in the theory of alternative method validation outside the area of genotoxicity testing have been discussed extensively since the late 1980s. In 1987, Scala (2) reviewed the characteristics of a valid test with particular emphasis on calculating the sensitivity, specificity, and predictive value of new test methods. Shortly thereafter, Frazier defined validation as "the process whereby the reliability and relevance of an alternative method is demonstrated for a particular purpose" (3) . At approximately the same time, the Amden I Workshop further defined important theoretical aspects related to the validation process (4) . Five years later the Amden II Workshop (5) focused on more practical aspects of validation that had been learned during several large multicenter validation studies that were initiated shortly after the Amden I Workshop. The Center for Alternatives to Animal Testing contributed numerous important documents in this time frame that also developed concepts related to the validation process (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The Multicentre Evaluation of In Vitro Cytotoxicity program also contributed significandy to the development of theoretical aspects of the validation process (21, 22) .
Validation of alternative methods has also been of considerable interest to regulatory authorities. Consequently, several international organizations, regulatory agencies, and committees have reviewed various aspects of validation and regulatory acceptance of alternative methods. The U.S. Interagency Regulatory Alternatives Group, which comprises scientists from the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, and the U.S. Consumer Products Safety validation and regulatory acceptance of alternative methods (24) . The European Commission formed the European Centre for the Validation of Alternative Methods (ECVAM), which plays a leading role in facilitating the optimization (prevalidation) and validation of alternative methods. ECVAM has contributed extensively to the field of validation in the form of publications on prevalidation (25) , and validation (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) , ECVAM workshop reports on the status of method development for a wide range of toxicity end points , and ECVAM task force reports (25, 62) . ECVAM has also coordinated validation studies on eye irritation testing (63) , photo irritation (64) , and skin corrosion (42) . Finally, the Organisation for Economic Co-operation and Development (OECD) test guidelines program has produced an important report on the harmonization and validation of alternative toxicological test methods (65) .
This paper summarizes some important aspects of the validation process that have been developed through these efforts. This discussion focuses on the replacement of animal tests that are currendy used to determine the hazard of chemicals for regulatory purposes. It provides guidance on the design, execution, and evaluation of validation programs. It also describes how to objectively assess the performance of the alternative methods relative to the in vivo test to be replaced and discusses the factors that must be considered when the relevance ofan alternative method is assessed. The concepts presented in this review are consistent with and expand on those developed by Frazier (3) , the Amden Workshops (4, 5) , the ICCVAM (24) , and OECD (65) reviews on validation, and other recent publications on the validation process (12, 13, 66) .
Definition of Validation
Validation has been defined as "the establishment of the reliability and relevance of an alternative method for a specific purpose" (3, 4) . To (66) .
Once the reproducibility of an alternative method has been confirmed, then its relevance must be evaluated. Relevance has been defined as establishing the scientific meaningfulness and usefulness of results from an alternative method for a particular purpose (3, 4) . Establishing usefulness and meaningfulness is important because hazard predictions obtained from scientifically credible alternative methods have a higher probability of being correct. To establish relevance, all available information related to the fundamental scientific basis, reliability (as defined above), and practical operation of the alternative method, and to the in vivo toxicity test to be replaced must be thoroughly reviewed. Ultimately, a judgment must be made about whether or not a method is relevant for a particular purpose.
Prevalidation of Alternative Methods
A method must be sufficiently developed before it is considered ready for evaluation in a validation study (Figure 1) (25, 66 inidal design and development (empirical or mechanistic basis) Figure 1 . The validation of an alternative method. The flow chart depicts one of several possible approaches that may be used as guides to design and conduct a validation program. The steps on the left side of the chart represent the validation process. The pathway within the shaded box represents the validation study process. The right side of the chart depicts the steps associated with improving the performance of the alternative method and defining another prediction model prior to inclusion of the method in a subsequent validation study. Any new method, whether based on a fundamental understanding of toxic mechanisms or on empirical correlations, may be assessed for validity using this approach. From Bruner et al. (66) . evaluated in the alternative method (66) . Ideally, all data supporting the validity of the test method should be obtained and reported in accordance with Good Laboratory Practices (24, 65 608 Computer simulations were used to assess the effects of variability in eye irritation test and alternative method data on the correlation coefficients expected between the data sets. The model used in the simulation assumed that the algorithm y=(1.1)xdescribes the relationship between the in vivoand alternative method data. Values for x= 0-100 were used to simulate responses across the entire Draize eye irritation scale. The simulations were conducted with test substances having the full range of response (x= 1-100) and for a restricted range representing the least irritating part of the eye irritation scale (x= 1-40). Each result is based on 10,000 runs of the simulation. Results are shown for the simulations where the variability is set relatively low (ideal conditions), and where the variability was set at a level consistent with performance of currently available alternative methods and the in vivo test (practical conditions). Additionally, simulations were conducted where the variability was set at zero for the alternative method (theoretical best conditions) and where the variability of the altemative method was set equivalent to the eye irritation test (alternative method equivalent to in vivo). The results of these simulations demonstrate that variability in the data sets can have a significant effect on the performance of the alternative method in predicting the in vivo response. Thus, the effect of variability must be taken into account when the performance of an alternative method is assessed. (Figure 3) . The 95% CIpred in this case will be approximately ± 35 for a predicted MAS of 55 (Table 2) . ±50.6 Computer simulations were used to assess the effects of variability in eye irritation test and alternative method data on the 95% Cipred. For predictions of in vivo scores from an alternative method result, the model used in the simulation assumed that the algorithm, y=(1.1)x, describes the relationship between the in vivo and alternative method data. Values for x=0-100 were used to simulate responses across the entire Draize eye irritation scale. For predictions of in vivo scores from the in vivo result, the model used in the simulation assumed that the algorithm, y=x, describes the relationship between the two sets of data. Each result is based on 10,000 runs of the simulation. The coefficient of variation (CV) for the alternative method was set at 20%. The CV used for the in vivo data ranged from 40-60% which is consistent with reports in the scientific literature (69). Once this information has been assembled and evaluated, the overall relevance of the method for its defined purpose must be assessed. If the conclusion is that the alternative method is not relevant, the test cannot be considered valid, and it is necessary to consider whether there is value in optimizing the assay, developing a new prediction model, and assessing it in a subsequent validation study (Figure 1) . Conversely, if the data support its relevance, that would suggest the alternative method may be used in the safety assessment process and should be considered for official acceptance by regulatory authorities (Figure 1 ). To gain regulatory acceptance, regulatory authorities and independent reviewers should receive all data supporting the conclusions obatined from the program so that the results and conclusions can be given a complete peer review (24) . Publication of results in a high-quality, peer-reviewed journal provides additional credibility to the conclusions obtained from a study (24) .
Conclusion
The reliability and relevance of an alternative method for a specific purpose are established during the (70) . In addition to facilitating objective assessment of the predictive capacity of an alternative method, the prediction model is also an important tool that can be used to guide the design of a validation study.
When the models used for making the predictions are stated at the beginning of a validation study, statisticians can use the information to provide data-based advice on such things as the numbers oftest substances to be included in the reference set of test substances, the number of participating laboratories needed, and the range of toxicity needed to adequately assess alternative method performance. Thus, the incorporation of the prediction models into the validation process at the beginning not only improves a reviewer's ability to assess the validity of an alternative method, but also has the potential to decrease the cost and time required to validate an alternative method by facilitating better study design. This is particularly important given the high costs oflarge, multicenter validation studies.
The computer simulations on the Draize eye irritation test provide a striking view of the results that can be expected from a validation study if the level of uncertainty in the data from the reference test to be replaced is high. In such cases, it will not be possible to demonstrate that alternative methods provide predictions that have high levels of certainty. As noted earlier, one of the most important factors to consider in the design of a validation study is to assure that the quality of data used for comparisons against the alternative method results are as high as possible. It has become apparent that obtaining test substances with high quality in vivo data is a difficult problem that must be overcome if rapid progress in the development and validation of alternatives is to be made. The simulations also demonstrate why it is important to establish objective criteria to be used as the basis for judging alternative method performance. The establishment of data-based performance benchmarks will better guide reviewers of a validation study in setting realistic performance expectations given the real-world technical limitations characteristic of the current state of the art (69, 71, 72) .
